Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis

Clinical Cancer Research

Volumn 13, Issue 3, 2007, Pages 795-798

  Roberts, David D ^a,b   Isenberg, Jeffery S ^a   Ridnour, Lisa A ^a   Wink, David A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BEVACIZUMAB; CD36 ANTIGEN; CD47 ANTIGEN; CISPLATIN; CYCLIC GMP; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GUANYLATE CYCLASE; INTERLEUKIN 2; ION CHANNEL; ISOSORBIDE MONONITRATE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RANIBIZUMAB; THROMBOSPONDIN 1; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; LOW DRUG DOSE; MOUTH CARCINOMA; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1;

EID: 33847414524     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1758     Document Type: Review

References (67)

1. Cao Y. Tumor angiogenesis and therapy. Biomed Pharmacother 2005;59:S340-3.
2. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 2006:223-68.
3. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and post-vascular dormancy. Cancer Res 1999;59:4770-5.
4. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
5. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
6. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-201.
7. Bagley RG, Weber W, Rouleau C, Teicher BA. Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res 2005;65:9741-50.
8. Bagley RG, Walter-Yohrling J, Cao X, et al. Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res 2003;63:5866-73.
9. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-51.
10. Scharovsky OG, Binda MM, Rozados VR, Bhagat S, Cher ML, Bonfil RD. Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance. Clin Exp Metastasis 2004;21:177-83.
11. Kiselev SM, Lutsenko SV, Severin SE, Severin ES. Tumor angiogenesis inhibitors. Biochemistry (Mosc) 2003;68:497-513.
12. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc 2000;5:40-6.
13. Pettet G, Chaplain MA, McElwain DL, Byrne HM. On the role of angiogenesis in wound healing. Proc Biol Sci 1996;263:1487-93.
14. Isenberg JS, Ridnour LA, Espey MG, Wink DA, Roberts DD. Nitric oxide in wound-healing. Microsurgery 2005;25:442-51.
15. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999;18:5356-62.
16. Alani RM, Silverthorn CF, Orosz K. Tumor angiogenesis in mice and men. Cancer Biol Ther 2004;3:498-500.
17. Strohmeyer D. Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer. Anticancer Res 1999;19:1557-61.
18. Kapila V, Sellke FW, Suuronen EJ, Mesana TG, Ruel M. Nitric oxide and the angiogenic response: can we improve the results of therapeutic angiogenesis? Expert Opin Investig Drugs 2005;14:37-44.
19. Murohara T, Asahara T. Nitric oxide and angiogenesis in cardiovascular disease. Antioxid Redox Signal 2002;4:825-31.
20. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des 2003;9:521-30.
21. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998;19:711-21.
22. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003;34:955-68.
23. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001;2:149-56.
24. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-24.
25. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004;10:143-5.
26. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A 2005;102:13141-6.
27. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A 2005;102:13147-52.
28. Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol 1997;37:339-59.
29. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J 1989;3:31-6.
30. Hofseth LJ, Saito S, Hussain SP, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A 2003;100:143-8.
31. Espey MG, Miranda KM, Pluta RM, Wink DA. Nitrosative capacity of macrophages is dependent on nitric-oxide synthase induction signals. J Biol Chem 2000;275:11341-7.
32. Yamasaki K, Edington HD, McClosky C, et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest 1998;101:967-71.
33. Takahashi S, Mendelsohn ME. Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J Biol Chem 2003;278:30821-7.
34. Chen JX, Lawrence ML, Cunningham G, Christman BW, Meyrick B. HSP90 and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery endothelium. J Appl Physiol 2004;96:612-20.
35. Bucci M, Roviezzo F, Cicala C, Pinto A, Cirino G. 17-beta-oestradiol- induced vasorelaxation in vitro is mediated by eNOS through hsp90 and akt/pkb dependent mechanism. Br J Pharmacol 2002;135:1695-700.
36. Babaei S, Teichert-Kuliszewska K, Zhang Q, Jones N, Dumont DJ, Stewart DJ. Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol 2003;162:1927-36.
37. Fontana J, Fulton D, Chen Y, et al. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 2002;90:866-73.
38. Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 2005;17:578-83.
39. Urbich C, Reissner A, Chavakis E, et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J 2002;16:706-8.
40. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006;5:522-32.
41. Dikalov S, Landmesser U, Harrison DG. Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling. Implications for studies of Hsp90 and endothelial cell nitric-oxide synthase. J Biol Chem 2002;277:25480-5.
42. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996;10:1183-91.
43. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1-12.
44. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004;36:1038-45.
45. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol 2000;19:597-614.
46. Calzada MJ, Roberts DD. Novel integrin antagonists derived from thrombospondins. Curr Pharm Des 2005;11:849-66.
47. Esemuede N, Lee T, Pierre-Paul D, Sumpio BE, Gahtan V. The role of thrombospondin-1 in human disease. J Surg Res 2004;122:135-42.
48. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonises nitric oxide stimulated vascular smooth muscle cell responses. Cardiovasc Res 2006;71:785-93.
49. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006;281:26069-80.
50. Sorbera L, Bayes M. ABT-510: oncolytic Angiogenesis Inhibitor. Drugs of the Future 2005;30:1081-6.
51. Eldesoky ES. Effect of acute inhibition of nitric oxide synthesis by I-NAME on cardiovascular responses following peripheral autonomic blockade in rabbits. Pharmacol 2006;20:239-45.
52. De Angelis K, Ogawa T, Sanches IC, Vianna Rigatto K, Krieger EM, Irigoyen MC. Impairment on cardiac output and blood flow adjustments to exercise in L-NAME-induced hypertensive rats. J Cardiovasc Pharmacol 2006;47:371-6.
53. Ascierto PA, Scala S, Castello G, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23:7660-8.
54. Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresect-able hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004;22:1815-22.
55. Cheng PN, Leung YC, Lo WH, Tsui SM, Lam KC. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma Cancer Lett 2005;224:67-80.
56. G-methyl- L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med 1995;23:1018-24.
57. Downie IP, Umar T, Boote DJ, Mellor TK, Hoffman GR, Brennan PA. Does administration of isosorbide mononitrate affect cellular proliferation in oral squamous cell carcinoma? A prospective randomized clinical study. J Oral Maxillofac Surg 2004;62:1064-8.
58. Di Napoli M, Papa F. NCX-4016 NicOx. Curr Opin Investig Drugs 2003;4:1126-39.
59. Rao CV, Reddy BS, Steele VE, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006;5:1530-8.
60. Hamano Y, Sugimoto H, Soubasakos MA, et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004;64:1570-4.
61. Haviv F, Bradley MF, Kalvin DM, et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 2005;48:2838-46.
62. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005;23:5188-97.
63. Yap R, Veliceasa D, Emmenegger U, et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005;11:6678-85.
64. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer 2006;42:467-72.
65. Gietema JA, Hoekstra R, de Vos FY, et al. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 2006;17:1320-7.
66. Rofstad EK, Galappathi K, Mathiesen B. Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts. Int J Radiat Oncol Biol Phys 2004;58:493-9.
67. Rofstad EK, Henriksen K, Galappathi K, Mathiesen B. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res 2003;63:4055-61.